Angiographic findings in patients with refractory Unstable angina according to troponin T status

• Published in: Circulation (New York, N.Y.) N.Y.), 1999-10, Vol.100 (14), p.1509-1514
• Main Authors: HEESCHEN, C, VAN DEN BRAND, M. J, HAMM, C. W, SIMOONS, M. L
• Format: Article
• Language: English
• Subjects: Abciximab; Adult; Aged; Angina, Unstable - blood; Angina, Unstable - diagnostic imaging; Angina, Unstable - drug therapy; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal - therapeutic use; Biological and medical sciences; Cardiovascular system; Coronary Angiography; Coronary Circulation - drug effects; Coronary Thrombosis - diagnostic imaging; Female; Humans; Immunoglobulin Fab Fragments - therapeutic use; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Middle Aged; Prospective Studies; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Troponin T - blood
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.CIR.100.14.1509

The CAPTURE (C7E3 fab AntiPlatelet Therapy in Unstable REfactory angina) trial enrolled patients with refractory unstable angina and documented a therapeutic benefit for abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist, that was particularly evident in patients with elevated troponin T (TnT) levels. In the current study, we related the angiographic data to the TnT status of the CAPTURE patients. In 853 patients, angiographic data at baseline and 18 to 24 hours after treatment were available and assessed by an Angiographic Committee with respect to TIMI flow, lesion severity, and visibility of thrombus. TnT levels >0.1 microg/L were found in 30.9% of the patients. Before randomization, thrombus was visible in 14.6% of TnT-positive patients (TnT levels >0.1 microg/L) and 4.2% of TnT-negative patients (P=0.004). Complex lesion characteristics B2+/C (72.0% versus 53.9%; P